Liquidia (NASDAQ:LQDA) Stock Sees Heavy Call Option Buying

Liquidia Corporation (NASDAQ:LQDA) saw unusually large options trading on Wednesday. Traders bought 30,594 call options on the company. This is an increase of 108% compared to the typical daily volume of 14,708 call options.

Insider Buying and Selling

In other news, insider Rajeev Saggar sold 50,000 shares of Liquidia stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $74.06, for a total transaction of $3,703,000.00. Following the sale, the insider owned 142,265 shares in the company, valued at $10,536,145.90. This trade represents a 26.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Roger Jeffs sold 32,744 shares of the business’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $932,549.12. Following the completion of the transaction, the chief executive officer directly owned 1,125,848 shares in the company, valued at $32,064,151.04. This trade represents a 2.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 745,194 shares of company stock worth $41,081,702 in the last quarter. 25.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. WINTON GROUP Ltd bought a new stake in Liquidia during the 2nd quarter valued at $335,000. Arizona State Retirement System grew its position in shares of Liquidia by 5.4% during the 2nd quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock worth $1,405,000 after buying an additional 900 shares in the last quarter. Nykredit A S bought a new position in shares of Liquidia during the 2nd quarter worth $177,000. Corient Private Wealth LP purchased a new position in shares of Liquidia during the second quarter valued at $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Liquidia during the second quarter valued at $1,236,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Trading Up 25.1%

Liquidia stock traded up $6.72 during mid-day trading on Wednesday, hitting $33.53. The company’s stock had a trading volume of 16,101,740 shares, compared to its average volume of 2,167,709. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The company has a 50 day moving average of $63.40 and a 200-day moving average of $61.76. Liquidia has a one year low of $21.94 and a one year high of $93.61. The stock has a market cap of $3.00 billion, a PE ratio of 24.81 and a beta of 0.61.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The company had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The firm’s revenue for the quarter was up 1842.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.49) earnings per share. On average, research analysts anticipate that Liquidia will post 2.05 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on LQDA shares. Zacks Research cut Liquidia from a “hold” rating to a “strong sell” rating in a report on Tuesday, September 22nd. BTIG Research raised shares of Liquidia from a “neutral” rating to a “buy” rating and set a $70.00 price objective for the company in a research note on Wednesday. Weiss Ratings raised shares of Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday, September 22nd. Wedbush set a $58.00 price objective on Liquidia in a research note on Friday, October 2nd. Finally, Citigroup reissued a “neutral” rating on shares of Liquidia in a research note on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $79.69.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: The agreement removes a major overhang and allows YUTREPIA inhalation powder to remain commercially available for pulmonary arterial hypertension (PAH) patients. Liquidia will not appeal the recent patent ruling, bringing greater certainty to the product’s commercialization. Liquidia settlement announcement
• Positive Sentiment: Preliminary third-quarter YUTREPIA sales totaled $222.7 million, contributing to $396.1 million of cash and cash equivalents at September 30. Management expects to fund the settlement and ongoing clinical programs through cash on hand and product sales without raising additional financing.
• Positive Sentiment: BTIG upgraded Liquidia to “buy” with a $70 price target, while Needham maintained a “buy” rating and set a $58 target. Both imply substantial upside from recent trading levels.
• Positive Sentiment: Call-option activity was unusually high, with 30,594 calls purchased—about 108% above typical daily volume—indicating increased speculative interest following the settlement.
• Neutral Sentiment: Multiple executives and other insiders sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested awards. The transactions reduce holdings but were not described as discretionary open-market sales, limiting their significance as a standalone signal.
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million, including $175 million within 30 business days, $60.3 million related to antitrust claims and $145.4 million in two 2027 installments. The payments will significantly reduce the company’s cash cushion and could constrain investment.
• Negative Sentiment: The company is removing the PH-ILD indication from YUTREPIA’s label and will stop promoting Treprostinil Injection, narrowing potential revenue opportunities despite preserving the PAH business.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).